On October 12 of 2016, ImmuneOnco Biopharma Co., Ltd., an emerging biotech company fully focusing on discovery and development of tumor immunotherapy, reported that, its first patent titled with "Recombinant Bi-functional Fusion Proteins, Preparations and Methods for Treating Disease" (U.S. Patent No. 14/666328) has been granted in the United States (Press release, ImmuneOnco Biopharma, OCT 12, 2016, View Source [SID1234519829]). This patent was originally invented by Macroimmune Inc which was acquired recently by ImmuneOnco. The new patent covers both composition-of-matter and method of treatment claims for the bi-functional protein. Related patent applications are pending in Europe, Japan, China and a number of other countries worldwide. Schedule your 30 min Free 1stOncology Demo! "The Bi-functional protein simultaneously targeting CD47/VEGF is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "The anti-angiogenesis activity of the protein will help shrink the tumor volume, making it more accessable to and easier for immune attack activated by the same protein blocking the SIRPa signals. We plan to file the IND of our novel bi-functional protein as early as late 2017 or early 2018." In preclinical studies, the combined inhibition of VEGF and SIRPa has resulted in significant anti-tumor activity in a variety of xenograft models.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!